3 05, 2023

Qkine officially opens new HQ and expanded manufacturing facility in Cambridge, UK

By |2023-05-10T10:55:31+00:00May 3rd, 2023|News, Press Release|Comments Off on Qkine officially opens new HQ and expanded manufacturing facility in Cambridge, UK

On Friday, 28th April 2023, Qkine officially opened its new HQ at Murdoch House, Cambridge, UK. We were delighted to be joined by Mayor Dr. Nik Johnson, the Mayor of Cambridge & Peterborough, alongside our team, customers, investors, and representatives from the Cambridge ecosystem.

15 12, 2022

Qkine raises over £4M to scale manufacturing, R&D and commercial functions

By |2023-04-21T08:58:08+00:00December 15th, 2022|News, Press Release|Comments Off on Qkine raises over £4M to scale manufacturing, R&D and commercial functions

Qkine Ltd, a manufacturer of animal-free, highly bioactive, and innovative proteins and growth factors for life science applications, announces the close of its oversubscribed funding raise, having secured £4.3M.

23 11, 2022

Qkine and 3D Bio-Tissues collaboration awarded €100,000 at EIT Food Venture Summit 2022

By |2022-11-23T06:46:58+00:00November 23rd, 2022|Awards, cellular agriculture, News, Press Release|Comments Off on Qkine and 3D Bio-Tissues collaboration awarded €100,000 at EIT Food Venture Summit 2022

A collaboration between Qkine and 3D Bio-Tissues has been awarded one of four prestigious prizes at the 2022 EIT Food Venture Summit, held in Lisbon, Portugal. Prize money will be used to develop new solutions to reduce the cost of cultivated meat.

1 08, 2022

Qkine secures lease on new premises to scale up manufacture

By |2022-08-01T14:53:31+00:00August 1st, 2022|News, Press Release|Comments Off on Qkine secures lease on new premises to scale up manufacture

Qkine secure a new lease on premises based in Cambridge city centre. The building will be transformed into modern agile lab and office spaces for research and process development, plus a dedicated, beta lactam free state of the art manufacturing suite.

11 03, 2022

List prices frozen until 2023

By |2022-03-11T16:14:30+00:00March 11th, 2022|News, Press Release|Comments Off on List prices frozen until 2023

Despite the ongoing challenges faced by the whole industry, we are demonstrating our commitment to supporting stem cell researchers by freezing our prices until January 1st, 2023. Furthermore, we will include free shipping on all orders moving forward.

10 09, 2021

Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

By |2021-09-10T18:53:50+00:00September 10th, 2021|Awards, cellular agriculture, News, Press Release, quality|Comments Off on Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, News, Press Release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

21 07, 2020

Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

By |2020-12-08T16:06:23+00:00July 21st, 2020|News, Press Release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

8 06, 2020

Qkine secures £1.5M series A funding from leading life science investors

By |2022-02-07T11:50:51+00:00June 8th, 2020|News, Press Release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors

Qkine secures £1.5M series A funding from leading life science investors Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global [...]

Title

Go to Top